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ABSTRACT The microsomal enzyme acyl-CoA:choles-
terol acyltransferase (ACAT; EC 2.3.1.26) catalyzes the ester-
ification of cellular cholesterol with fatty acids to form
cholesterol esters. ACAT activity is found in many tissues,
including macrophages, the adrenal glands, and the liver. In
macrophages, ACAT is thought to participate in foam cell
formation and thereby to contribute to atherosclerotic lesion
development. Disruption of the gene for ACAT (Acact) in mice
resulted in decreased cholesterol esterification in ACAT-
deficient fibroblasts and adrenal membranes, and markedly
reduced cholesterol ester levels in adrenal glands and peri-
toneal macrophages; the latter finding will be useful in testing
the role of ACAT and macrophage foam cell formation in
atherosclerosis. In contrast, the livers of ACAT-deficient mice
contained substantial amounts of cholesterol esters and ex-
hibited no reduction in cholesterol esterification activity.
These tissue-specific reductions in cholesterol esterification
provide evidence that in mammals this process involves more
than one form of esterification enzyme.
Cells of multicellular organisms are protected from excess free
cholesterol toxicity in part by acyl-CoA:cholesterol acyltrans-
ferase (ACAT; EC 2.3.1.26), a microsomal enzyme that es-
terifies cholesterol with fatty acids to form cholesterol esters,
which can then be stored in cytosolic droplets (1–4). This
process occurs in many tissues but is prominent in macro-
phages of atherosclerotic lesions, where large amounts of
cholesterol from lipoproteins are taken up by receptor-
mediated endocytosis (5), and in adrenocortical cells, where
cholesterol to be used as substrate for steroidogenesis is stored
as cytosolic cholesterol ester droplets. In macrophages, the
esterification of cholesterol by ACAT gives rise to macrophage
foam cells, a prominent feature of atherosclerotic lesions.
Because of ACAT’s role in foam cell formation and its
potential roles in intestinal cholesterol absorption (6) and
hepatic lipoprotein synthesis (7), pharmaceutical inhibitors of
ACAT have received considerable interest as possible thera-
pies for atherosclerosis; although these agents have shown
promise (8), their use in animals has been associated with
adrenal gland toxicity (9, 10).
The recent cloning of a cDNA for human ACAT by Chang
et al. (11) has facilitated a molecular genetic approach to
determining ACAT’s in vivo functions. In this study, we used
gene targeting in mouse embryonic stem (ES) cells to generate
mice deficient in ACAT. The ACAT-deficient mice had tissue-
specific reductions in cholesterol esterification, implying the
existence either of multiple ACAT isoforms or of another
not-yet-identified cholesterol esterification gene(s).
MATERIALS AND METHODS
Gene Targeting. Degenerate primers derived from the hu-
man ACAT cDNA sequence (11) were used to amplify a
310-bpmouse cDNA fragment. Using this fragment as a probe,
a 14-kb 129ySv genomic l clone was isolated, and sequencing
of this clone identified a 59 exon [amino acids 50–100 (12)]. To
construct a targeting vector, a 700-bp fragment that termi-
nated at amino acid 63 was amplified and cloned into the XhoI
site, and a 9-kb downstream BamHI genomic fragment was
ligated into theBamHI site of pPol2short-neobpA-HSVTK (13)
(provided by S. Ishibashi, University of Texas Southwestern
Medical School).
ES cells (RF8) were derived from 129yTerSv mice on feeder
layers of SNL76y7 fibroblasts (provided by A. Bradley, Baylor
College of Medicine, Houston) as described (14). Culture and
electroporation of ES cells were as described (14, 15). For
Southern blot analysis, ES cell genomicDNAwas digested with
EcoRI, and a'1-kbHindIII–SacI restriction fragment located
upstream of the vector sequences was used as a probe. For
PCR genotyping, genomic DNA was amplified with primer A
(59-CAGCTATGTACACACATATATTCATG-39), which is
located upstream of the targeting vector, primer B (59-
TTGGGAAGACAATAGCAGGCATGC-39), which is lo-
cated in the polyadenylylation signal of the neo gene (833-bp
product, targeted allele), and primer C (59-GGACTTT-
TCAATGAGGTTGGTCAC-39), which is unique to the de-
leted region of the wild-type allele (790-bp fragment, wild-type
allele). PCR conditions were 35 cycles, each of 30 sec at 968C,
1 min at 508C, and 2 min at 728C. Microinjection of targeted
clones and chimera generation were as described (15). The
mice described herein were of a mixed C57BLy6 and 129ySv
genetic background. Mice were housed in a pathogen-free
barrier facility operating on a 12-h lighty12-h dark cycle and
were fed either rodent chow (Ralston Purina) or a synthetic
diet (ICN) containing 15% fat and 1.25% cholesterol (16).
For Northern blotting, RNA was prepared from mouse
tissues (17) and analyzed by standard techniques. Blots were
probed with a 32P-labeled 501-bp ACAT cDNA fragment
[nucleotides 804–1304 (12)] or an end-labeled 28S primer (18)
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked ‘‘advertisement’’ in
accordance with 18 U.S.C. §1734 solely to indicate this fact.
Abbreviations: ACAT, acyl-CoA:cholesterol acyltransferase; ACTH,
adrenocorticotropic hormone; ES, embryonic stem; apo, apolipopro-
tein; HDL, high density lipoprotein; LDL, low density lipoprotein.
‡Present address: Institute of Pharmacological Sciences, via Balzaretti
9, 20133 Milano, Italy.
**To whom reprint requests should be addressed at: Gladstone Institute
of Cardiovascular Disease, P.O. Box 419100, San Francisco, CA
94141-9100. e-mail: bob_farese.gicd@quickmail.ucsf.edu.
14041
and were exposed to x-ray film overnight. For immunoblotting,
tissue homogenates were prepared as described (19), and
proteins were separated by SDSyPAGE on 4–20% gradient
gels; immunoblots were probed with polyclonal antibody
DM10 (19) (generously provided by T. Y. Chang, Dartmouth
University, Hanover, NH) and detected with an enhanced
chemiluminescence system (Amersham).
Cholesterol Esterification Assays.Murine embryonic fibro-
blast lines were generated (20), and fibroblasts (passages 3–5)
were pulse-assayed for cholesterol esterification as described
(21). For microsomal membrane assays, tissues were homog-
enized in buffer A (50 mM TriszHCl, pH 7.8y1 mM EDTAy1
mM phenylmethylsulfonyl f luoride) with a Polytron homoge-
nizer (Brinkmann, Westbury, NY); the microsomal membrane
fractions (100,000 3 g pellet) were isolated by sequential
centrifugation. For the adrenal gland assays, total membrane
homogenates (excluding nuclei) were used. The rate of incor-
poration of [14C]oleoyl-CoA (Amersham) into cholesterol
esters was assayed essentially as described by Erickson et al.
(22). Reactions were performed at 378C for 5 min with
100–150 mg of protein homogenate and 5 nM oleoyl CoA
(specific activity, '18 mCiymmol; 1 Ci 5 37 GBq). In some
experiments, exogenous cholesterol (20 nmol) was added to
the reaction by preincubating membranes for 30 min at 378C
with phosphatidylcholineycholesterol (4:1 molar ratio) lipo-
somes (23). CI-976 (a gift from R. Newton, Parke-Davis) was
dissolved in dimethyl sulfoxide; equivalent amounts of di-
methyl sulfoxide were added to control samples.
Plasma and Tissue Lipid Analysis. Total cholesterol, high
density lipoprotein (HDL) cholesterol, and triglycerides were
determined by colorimetric assays (24). Peritoneal macro-
phages were isolated as described (25). Macrophages were
cultured in serum-free Dulbecco’s minimal essential medium
containing 50 mgyml acetylated low density lipoproteins
(LDL) (26). For tissue cholesterol and cholesterol ester de-
terminations, lipids were extracted from tissue homogenates
by the Bligh–Dyer method (27) and separated by thin-layer
chromatography; extracted lipids were dissolved in isopropa-
nol and aliquots were measured for cholesterol content using
a colorimetric assay (Boehringer Mannheim). High-
performance thin-layer chromatography (HPTLC) was as
described (28).
Histologic Analysis. Perfusion-fixed (3% paraformaldehyde
in Tyrode’s solution) adrenal glands were frozen, sectioned
with a vibratome, and stained with Oil red O (29).
Adrenocorticotropic Hormone (ACTH) Stimulation Tests.
ACTH stimulation tests were performed on 8- to 12-week-old
male mice beginning at 9:00 a.m. (2 h into the light cycle). Mice
were anesthetized with tribromoethyl alcohol, a baseline
plasma sample was obtained, and mice were injected intra-
peritoneally with 1 unit of b1-24 ACTH (Cortrosyn, Organon).
After 1 h, the anesthetized mice were killed, and blood was
collected. Corticosterone was measured by a competitive
protein-binding assay (30) after HPTLC (31).
Cholesterol Absorption. Cholesterol absorption was meas-
ured with a fecal isotope ratio method that uses [14C]choles-
terol and [3H]sitostanol (32).
Statistics. Data are given as the mean 6 SD. The t test,
analysis of variance, and the Student Newman–Keuls test were
used to compare means between groups.
RESULTS
Acact Gene Disruption. A sequence-replacement vector
using a positive-negative selection strategy (33) was used to
disrupt the gene for ACAT (Acact) (Fig. 1A) in mouse ES cells
and subsequently generate mice homozygous for the gene
disruption (Acact2/2) (Fig. 1B). The Acact2/2 mice were
healthy, fertile, and grew normally. Northern blot analysis of
RNA from preputial glands, which express high levels of
ACAT (12), revealed that Acact2/2 mice had low levels of an
ACAT mRNA that was slightly smaller than the wild-type
mRNA (Fig. 1C). Sequencing of reverse transcription–PCR
products from Acact2/2 mRNA revealed that the truncated
mRNA arises from alternative splicing around the inserted neo
gene, resulting in a frameshift and a premature stop codon (see
legend to Fig. 1). Immunoblotting with an antibody (19) that
detects the amino-terminal region of ACAT demonstrated no
detectable ACAT protein in homogenates of preputial glands
ofAcact2/2mice (Fig. 1D) or in homogenates from ovaries and
adrenals (not shown), which also express high levels of ACAT.
No distinct band of the appropriate size for ACAT was found
in liver homogenates of either wild-type or Acact2/2mice. The
effect of the ACAT gene disruption on ACAT activity was
initially assessed by measuring cholesterol esterification in
embryonic fibroblasts (Fig. 1E). In contrast to that in wild-type
fibroblasts, esterification activity in Acact2/2 fibroblasts was
not stimulated in response to cholesterol provided by human
LDL; esterification activity was intermediate in heterozygous
fibroblasts. In addition, esterification activity in Acact2/2
fibroblasts was not stimulated by 25-hydroxycholesterol (not
shown). In the Acact2/2 fibroblasts, residual esterification
activity was found, which decreased upon the addition of LDL
to low but detectable levels (,10% versus wild-type) in most
experiments.
Cholesterol Ester Depletion in the Adrenal Glands and
Macrophages. In contrast to the opaque, whitish-yellow ap-
pearance of adrenals from wild-type mice (Fig. 2A), the
adrenal glands of Acact2/2 mice were translucent and brown-
ish, suggesting the depletion of cholesterol esters. Staining
with Oil red O demonstrated abundant lipid staining of the
adrenal cortex in sections from wild-type mice, no lipid
staining in Acact2/2 mice, and intermediate lipid staining in
heterozygous mice (Fig. 2B). Tissue lipid analysis revealed that
the cholesterol ester content of adrenal glands was markedly
reduced in the Acact2/2 mice (Table 1). Additionally, adrenal
cholesterol esterification activity was markedly lower in
Acact2/2 than in wild-type mice (406 16 versus 2966 42; P,
0.01) (see Fig. 4A).
To determine if the adrenal cholesterol ester depletion in
Acact2/2 mice resulted in diminished glucocorticoid produc-
tion in response to an acute stimulus, we measured serum
corticosterone levels before and 1 h after ACTH stimulation
in male wild-type and Acact2/2 mice. We observed no signif-
icant differences in either baseline (Acact1/1, 16.96 3.1 mgydl,
n 5 6; Acact2/2, 17.7 6 13.1 mgydl, n 5 5) or poststimulation
(Acact1/1, 33.86 4.0 mgydl, n5 6; Acact2/2, 33.86 8.1 mgydl,
n 5 8) levels between the groups.
The effects of ACAT deficiency on macrophage foam cell
formation were assessed by culturing peritoneal macrophages
with acetylated LDL. HPTLC of lipid extracts demonstrated
markedly lower cholesterol ester content in Acact2/2 macro-
phages than in wild-type cells, although trace amounts were
detectable (Fig. 3). Lipid quantitation confirmed the near
absence of cholesterol esters in Acact2/2 macrophages and
demonstrated that the free cholesterol content tended to be
higher in these cells (Table 1). Despite the marked reduction
in cholesterol esters, neutral lipid droplets, presumably con-
taining triglycerides, were observed in many of the Acact2/2
macrophages as assessed by Nile red fluorescence (not shown).
Hepatic Cholesterol Ester Metabolism. In contrast to the
adrenal glands, the livers of Acact2/2 mice contained substan-
tial amounts of cholesterol esters (Table 1). Hepatic choles-
terol ester levels were 30% lower in Acact2/2 mice than in
wild-type mice that were fed a chow diet but were similar in
wild-type andAcact2/2mice fed a high-fat diet (Table 1). Also,
cholesterol esterification in hepatic Acact2/2 microsomes was
not reduced compared with wild-type microsomes isolated
frommice fed either chow (Fig. 4B) or a high-fat diet (Fig. 4C).
The residual cholesterol esterification activity responded iden-
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tically inAcact2/2 and wild-type hepatic microsomes incubated
with the ACAT inhibitor CI-976 (Fig. 4D).
Cholesterol Absorption and Plasma Lipid Levels. Choles-
terol absorption was not significantly different in Acact2/2
(n5 9) and wild-type mice (n5 9) that consumed a chow diet
(74 6 15% versus 82 6 9%, respectively; P 5 0.20) or in
wild-type (n 5 2) and Acact2/2 mice (n 5 3) that consumed a
high-fat diet (37%6 0.7 and 41%6 5, respectively). When fed
a chow or high-fat diet, Acact2/2mice had higher plasma levels
of total and HDL cholesterol than wild-type mice (Table 2).
The increase in plasma HDL cholesterol in chow-fed mice was
confirmed by measuring the cholesterol concentration of
lipoproteins separated by gel filtration chromatography (not
shown). Plasma triglyceride levels were not different in
Acact2/2 and wild-type mice.
DISCUSSION
In this study, the disruption of the 59 region of Acact yielded
mice with tissue-specific reductions in cholesterol esters and
cholesterol esterification. In Acact2/2 mice, cholesterol esters
were markedly diminished in the adrenocortical cells and
cultured peritoneal macrophages, and cholesterol esterifica-
tion was markedly reduced in embryonic fibroblasts and
adrenal membranes; however, Acact2/2 livers contained sub-
stantial amounts of cholesterol esters, and hepatic cholesterol
esterification was not diminished. In addition, the gene dis-
ruption had no detectable effect on intestinal cholesterol
absorption, a process thought to involve a cholesterol esteri-
fication enzyme (6).
The adrenal lipid depletion phenotype in Acact2/2 mice is
similar to that in apolipoprotein (apo) AI knockout mice
reported recently by Plump et al. (34). In apo-AI-deficient
mice, the lack of apo-AI-containing HDL particles presumably
prevents adrenocortical cell uptake of cholesterol esters via the
‘‘selective uptake’’ pathway (35), resulting in the depletion of
the cytosolic cholesterol ester droplets. Our findings suggest
that cholesterol molecules taken up by the selective uptake
pathway as cholesterol esters are hydrolyzed and subsequently
FIG. 1. Generation of Acact2/2 mice. (A) Targeting vector strategy. Homologous recombination of the vector results in the interruption of a
59 early exon (amino acids 50–100) of ACAT by the neo gene (at amino acid 63 of 540) and causes a '2-kb deletion of genomic sequences (striped
bar). Targeted clones were identified by a unique 4.4-kb EcoRI restriction fragment as detected by a '1-kb HindIII–SacI probe located upstream
of the vector or by PCR analysis. Targeting frequency was 1 in 268. (B) Southern blot demonstrating Acact2/2 mice. Of 226 offspring from
heterozygous matings, 66 were wild-type mice, 104 were heterozygotes, and 56 were homozygotes (P 5 0.573 by x2 analysis versus the expected
1:2:1 Mendelian distribution). (C) Northern blot of preputial gland RNA in Acact2/2mice. Blots were probed with a mouse ACAT cDNA fragment
and reprobed with a primer specific for 28S RNA to control for RNA sample loading. Reverse transcription–PCR analysis (not shown) revealed
that the shorter ACATmRNA inAcact2/2mice was caused by exon skipping around the inserted exon containing the neomutation and the following
exon, which was deleted in the targeting vector. The skipping of these two exons generates a 211-bp deletion and a frameshift resulting in a premature
stop codon. (D) Immunoblot demonstrating lack of ACAT protein in preputial gland homogenates from Acact2/2 mice. Each lane contains 100
mg of protein; membranes were incubated with DM10 (19). As a control, the same homogenates were tested for the LDL receptor–related protein,
which was detectable at approximately equivalent amounts in each sample (not shown). (E) Cholesterol esterification activity in embryonic
fibroblasts in response to LDL. Pulse assays were performed as described (21) on fibroblasts derived from Acact1/1, Acact1/2, or Acact2/2 embryos.
The experiment was repeated three times; data from a representative experiment are shown.
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re-esterified by ACAT for storage as cytosolic cholesterol ester
droplets. Interestingly, we (36) and others (12) recently
mapped the mouse ACAT gene to a region of chromosome 1
that contains ald (37), a naturally occurring adrenal lipid
depletion locus that occurs as an autosomal recessive trait in
AKR inbred mice (38). Studies to determine if the ald phe-
notype is due to an ACAT mutation are in progress. To our
knowledge, a similar adrenal lipid depletion disorder in hu-
mans has not been reported.
The dramatic cholesterol ester depletion in Acact2/2 adre-
nocortical cells had no discernible effect on adrenal steroido-
genesis in response to an acute ACTH stimulus in male
Acact2/2 mice. In apo-AI-deficient mice, plasma corticoste-
rone responses to ACTH stimulation or swimming stress tests
were blunted, especially in males (34). The different responses
in the apo-AI-deficient mice and theAcact2/2micemay reflect
different degrees of stress or stimulation; alternatively, the
provision of cholesterol through the selective uptake pathway
may be more critical for steroidogenesis than cytosolic cho-
lesterol ester pools during acute stress. In both mouse models,
however, adrenal glucocorticoid production responded re-
markably well to acute stimulation despite the dramatic de-
pletion of cholesterol esters in the cells.
Cholesterol esters were also decreased in cultured perito-
neal macrophages from Acact2/2 mice. When incubated with
acetylated LDL, macrophages from the Acact2/2 mice had a
marked reduction in their ability to accumulate the cholesterol
esters that are characteristic of macrophage foam cells in
atherosclerotic lesions. It will be of interest to determine
whether ACAT deficiency and reduced foam cell formation
will protect against the development of atherosclerotic lesions.
This could be assessed by breeding the Acact2/2 mice with
FIG. 2. Adrenal lipid depletion in Acact2/2 mice. (A) Gross
appearance of adrenal glands from male Acact1/1, Acact1/2, and
Acact2/2 mice. The scale at the bottom of the photograph is in
millimeters. (B) Oil red O-stained sections showing absence of neutral
lipids in adrenal cortex of male Acact2/2 mice. Identical findings were
observed in female mice. Staining in the heterozygous mice was
consistently confined to a smaller area of the zona fasciculata.
FIG. 3. HPTLC of lipid extracts from wild-type or Acact2/2
peritoneal macrophages demonstrating reduced macrophage choles-
terol ester accumulation in Acact2/2mice. Macrophages were isolated
from male mice and incubated with acetylated LDL (50 mgyml) for
36 h. Lipid extracts were pooled and analyzed by HPTLC (28).
Equivalent amounts of lipid extract (from '3 mg of protein homog-
enate) were loaded in each lane; each lane represents lipids from four
mice.
Table 1. Cholesterol ester and free cholesterol content of tissues
Tissue
Acact
genotype n
Lipid content,
mgymg protein
CE FC
Adrenal 1y1 3 105.4 6 9.7 11.5 6 2.7
1y2 3 53.9 6 5.1† 10.3 6 2.3
2y2 3 3.3 6 0.6† 7.1 6 0.6
Liver 1y1 5 2.7 6 0.1 9.5 6 1.7
Chow diet 2y2 5 1.9 6 0.5† 8.7 6 2.5
Liver 1y1 3 346.0 6 119 30.5 6 8.3
High fat diet 2y2 3 350.0 6 42 31.0 6 4.3
Peritoneal 1y1 2* 130.0 6 33 36.1 6 1.2
macrophages 2y2 3* 7.9 6 4.8† 72.3 6 23.8‡
Data are x¯ 6 SD. Data are from female mice except for peritoneal
macrophages, which were obtained from male mice. CE, cholesterol
ester; FC, free cholesterol.
*Each sample represents pooled lipid extracts of macrophages from
four mice.
†P , 0.01 vs. 1y1.
‡P 5 0.13 vs. 1y1.
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atherosclerosis-susceptible strains, such as apo-E-deficient
(39, 40) or LDL receptor-deficient mice (41). With regard to
atherosclerosis studies, it is noteworthy that the Acact2/2mice
had increased plasma total and HDL cholesterol levels. The
mechanism for this unexpected finding remains to be deter-
mined. The increased HDL cholesterol levels could be due to
the effects of ACAT deficiency on cholesterol metabolism, but
could also result from the effect of a strain 129-derived allele
linked to the targeted locus [e.g. Ath-1 (42) affects plasma
HDL levels and maps close to Acact].
In contrast to its effects on adrenal glands and macrophages,
the gene disruption had little effect on hepatic cholesterol ester
metabolism. Although the livers of Acact2/2 mice fed a chow
diet had a modest decrease in cholesterol ester content, this
was not the case when the mice were fed a cholesterol-rich diet.
Further, hepatic cholesterol esterification activity was not
reduced in Acact2/2mice. These results are consistent with the
low level of ACAT mRNA in hepatocytes (12, 43) and our
inability to detect ACAT in immunoblots of mouse hepatic
tissue. Taken together, these findings suggest that mouse liver
contains a form of cholesterol esterification enzyme distinct
from the enzyme we inactivated.
At least two possible explanations could account for an
alternative cholesterol esterification enzyme. First, there may
be another, not-yet-identified cholesterol esterification en-
zyme(s). Both biochemical (44) and ACAT inhibitor (45) data
have suggested that there is more than one esterification
enzyme in mammals, and Yang et al. (46) have recently
identified two sterol esterification enzymes in yeast, both of
which must be inactivated to abolish sterol esterification. Of
note, both we and Yang et al. (46) have identified human
cDNAs from expressed sequence tag data bases that are
ACAT homologues and that share extensive regions of identity
with ACAT in the carboxyl terminus. These cDNAs appear to
be members of an ACAT gene family, but it remains to be
determined if the proteins they encode can esterify cholesterol.
Second, it is possible that a currently unrecognized alternative
splicing of ACAT mRNA occurs in the liver, and that the gene
disruption did not inactivate a liver-specific ACAT isoform.
Although we and others (12) have no evidence supporting the
encoding of different ACAT isoforms from the Acact locus,
this remains a possibility.
In summary, our study provides evidence suggesting that
more than one form of cholesterol esterification enzyme exists
FIG. 4. Cholesterol esterification activity in adrenal membranes and hepatic microsomes of wild-type andAcact2/2mice. (A) Adrenal membrane
activity in female mice. Assays were performed with 100 mg of protein as described in Materials and Methods. Results are shown for three samples
for each genotype; each sample contained pooled adrenals from two mice. Exogenous cholesterol (20 nmol) in the form of liposomes was added
during the preincubation. p, P , 0.01 versus Acact1/1. (B) Hepatic membrane activity of female mice fed a chow diet. Assays were performed with
150 mg of protein in the presence or absence of 20 nmol of exogenous cholesterol provided as liposomes during preincubation (Acact1/1, n 5 3;
Acact2/2, n5 3). (C) Hepatic membrane activity of mice fed a high-fat, high-cholesterol diet. Assays were performed with 150 mg of protein without
added cholesterol (Acact1/1, n 5 3; Acact2/2, n 5 3). P 5 0.20 for the difference between means. (D) Effects of the ACAT inhibitor CI-976 (10
mgyml) on cholesterol esterification activity of hepatic microsomes from chow-fed mice. Assays were performed after preincubation with exogenous
cholesterol.
Table 2. Plasma lipids of wild-type and ACAT-deficient mice
Diet
Acact
genotype n
Plasma lipid concentration, mgydl
TC HDL-C TG
Chow* 1y1 8 57 6 19 48 6 12 60 6 20
1y2 5 70 6 19 52 6 13 57 6 7
2y2 7 123 6 29‡§ 83 6 19‡§ 63 6 22
High-fat† 1y1 8 170 6 61 54 6 18 35 6 17
1y2 10 207 6 56 66 6 21 35 6 12
2y2 10 240 6 48‡ 89 6 21‡§ 29 6 9
Data are x¯ 6 SD. TC, total cholesterol; HDL-C, HDL cholesterol;
TG, triglycerides.
*Female mice fed standard chow for 3–5 months.
†Male and female mice fed a high-fat, high-cholesterol diet for 6–10
weeks.
‡P , 0.05 vs. 1y1.
§P , 0.05 vs. 1y2.
Medical Sciences: Meiner et al. Proc. Natl. Acad. Sci. USA 93 (1996) 14045
in mammals. Such a redundancy in the cellular cholesterol
esterification pathway may have contributed to the healthy
phenotype we observed in Acact2/2 mice. Interestingly, the
gene we disrupted was cloned from macrophages (11), and the
two tissues in which we observed a phenotype—the adrenal
gland and macrophages—both process large cholesterol loads
and are characterized by large cytosolic cholesterol ester
droplets. Insights into the molecular aspects of different
cholesterol esterification enzymes could lead to the develop-
ment of more selective cholesterol esterification enzyme in-
hibitors of specific processes, such as macrophage foam cell
formation or hepatic lipoprotein production.
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